What are CAR-T cells?

CAR T cells, or chimeric antigen receptor T cells, are a type of genetically engineered immune cell that targets cancer cells in a patient's body. They are modified T cells extracted from a patient's blood and reprogrammed with CAR molecules that allow them to recognize and attack cancer cells. Once infused back into the patient, the CAR-T cells multiply and actively seek out and destroy cancer cells.

What is a chimeric antigen receptor?

A chimeric antigen receptor (CAR) is a receptor protein artificially engineered to attach to the surface of immune cells . It consists of an extracellular domain that binds to specific antigens on cancer cells, and an intracellular domain that activates the immune cell to kill the targeted cancer cell. CARs are engineered in the laboratory and can be used in immunotherapy to treat cancer by enhancing the immune system's ability to destroy cancer cells.

How are CAR-T cells made?

CAR T cells are made by collecting T cells from a patient's blood and genetically engineering them to express a chimeric antigen receptor (CAR) that recognizes and binds to a specific antigen on the cancer cell's surface. The engineered CAR-T cells are expanded in the lab and then infused back into the patient. Once inside, the CAR-T cells locate and bind to cancer cells, triggering an immune response that destroys the cancer cells.

Solutions

Online Inquiry

One-Stop CAR-T Therapy Development Solutions

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Services Platforms Advantages Resources Related Sections

Immunotherapy has become a revolution in the area of cancer treatment. Compared to the traditional methods, such as invasive surgeries, radiation and chemotherapy, immunotherapy is more specific and less toxic to patients. Chimeric antigen receptor (CAR)-engineered T cell therapy is the most promising approach, which has shown remarkable ability to eliminate various kinds of tumors, especially for B cell malignancies, with up to 95% response rates and durable complete remission. A CAR mainly consists of a single chain variable fragment (scFv) from a monoclonal antibody which binds a specific antigen, a hinge and spacer element, a trans-membrane region and an internal signaling domain such as CD3ζ. The main advantage of CAR-T cell is that it bypasses MHC restriction, which allows for direct activation of effector cells for the treatment of various types of tumors.

Creative Biolabs is a world-renowned service provider for immunotherapy. We have one of the world's largest collection of CAR products of different generations targeting various biomarkers, and we continue to innovate the next generation CAR technologies to achieve even greater results. Based on advanced technology and years of research, Creative Biolabs offers high-quality custom service covering the entire CAR-T therapy development process to best suit your technical, program and budget requirements which can greatly assist your research, preclinical investigation and clinical stage development.

CAR-T Therapy Development Solutions

Biomarker Identification & Selection High Affinity ScFv Generation CAR Design & Construction Virus Packaging & CAR Gene Delivery CAR-T In Vitro Assay CAR-T Preclinical In Vivo Assay CAR-T Clinical Trial

De novo discovery of potential cancer biomarkers by multiple gene and protein analysis technologies
Selection of the most suitable CAR-T therapy targets with greater potency and lower toxicity

In-house inescapable antibody sequence data base
A collection of over 6000 antibody products
Antibody discovery by hybridomas, mouse, rabbit and human library
ScFv sequencing and NGS of hybridomas or phage libary
ScFv affinity measurement and optimization

Design and construction of CARs of different generation
Smart™ CAR platform for the next generation CAR discovery
Customized lentiviral or retroviral CAR construction

High titer transduction-ready pseudoviral particles produced by our cell manufacture platform
GMP virus manufacturing for clinical trials and applications
Strict quality control
Various transfection technology available
Transfection method tailored for different cell types

CAR expression validation
CAR-T cell proliferation
Multiplex cytokine screening
Cytotoxicity test against target cells

Construction of Xenograft Animal Model
Efficacy Test of CAR-T cells
Viability and Bio-distribution Study of CAR-T cells
Toxicity Evaluation of CAR-T cells
GLP-compliant assays

Study design and filing
Project management and execution
Data management and biostatistics
QA&QC

CAR-T Cell Platforms

Despite the classical 1st-4th generations of CARs, our Smart™ CAR platform allows to provide construction services of novel CAR designs, such as Dual CAR, TriCAR, Modular CAR, Logic-gated CAR.

Smart™ CAR Construction

We have established a safer approach to cell therapy through the transient expression and non-viral delivery of one or more mRNA molecules into PBMCs or isolated immune cells.

mRNA-Based CAR Cell Platform

We can carry out scFv generation from hybridoma cell line through the converting full immune globulin into a scFv using a short flexible linker or phage display library.

CAR-T Cell Display Platform

Such methods include knocking out endogenous genes to construct allogeneic universal CAR-T cells, destroying inhibitory receptors and integration of the CAR cassette.

CRISPR-edited CAR Cell Technology

This technology platform provides an unlimited source of engineered stem cell-derived CAR-T/NK/MA immune cells to eliminate cancer cells or regulate the tumor microenvironment.

CAR-Stem Cell Platform

Highlights & Advantages

Fully custom services are adapted according to your project.
One-stop solutions from biomarker discovery, CAR cell production, to preclinical/clinical validation.
Available to construct the classical, novel, and special CAR designs, and easily to submit a custom CAR design online with a few clicks.
Professional team with extensive experience in cell engineering, supporting you at every stage of your project.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

VideosPodcastsInfographicFlyer Support Knowledge

Webinar: Engineering strategies for improving adoptive T cell therapy

Webinar: Convertible CAR-T, a highly adaptable CAR-T platform

Chimeric antigen receptor CAR Technique

Advances in CAR-T Cell Therapy

Understand CAR-T Therapy by One Graphic

Evolution of Chimeric Antigen Receptor Design

CAR-T Cell Immunotherapy: Development of CAR-T Cells

CAR-T Cell Immunotherapy: Clinical Applications and Challenges

CAR-T Cell Immunotherapy: Basic Principles

Obstacles and Potential Strategies in CAR-T Therapy

One-Stop CAR-T Therapy Development

CAR-T Cell In Vitro Assay Services

CAR Design & Construction Service

CAR-T Preclinical In Vivo Assay

Overview of Chimeric Antigen Receptors

Chimeric antigen receptor (CAR) can combine the extracellular antigen recognition domain from antibodies with the immune cell signaling domain to redirect T cell specificity and induce potent antitumor activity. CAR is an artificial transmembrane receptor that connects the extracellular antigen recognition domain, hinge domain (HD), transmembrane domain (TMD), and intracellular signal transduction domain in series.

Overview of CAR-T Cell Therapies

CAR-T cell therapies revolutionize cancer treatment by harnessing the power of a patient's immune cells. Engineered with chimeric antigen receptors (CARs), these cells effectively target and destroy cancer cells, offering a personalized and potent approach. This groundbreaking immunotherapy has shown remarkable success in treating certain blood cancers, providing hope for patients who may not respond to traditional treatments. CAR-T cell therapies mark a significant stride towards precision medicine, ushering in a new era in oncology with the potential to transform the landscape of cancer care.

T Cell-based Immunotherapies

Based on the significant roles of T cells in the immune system, many small-molecule drugs targeting T cells and T-cell based immunotherapies have been developed for the treatment of intractable diseases including autoimmune diseases and cancer. T cell-based immunotherapies mainly utilize the mechanisms of T cell-mediated immune responses and the effects of some other immune cells such as dendritic cells (DCs), natural killer (NK) cells, and macrophages.

Adoptive Transfer of Genetically Engineered T Cells

Adoptive cell transfer (ACT) of engineered T cells is a cutting-edge therapeutic approach revolutionizing cancer treatment. This innovative method involves modifying T cells, a key component of the immune system, to enhance their ability to target and eliminate cancer cells. By introducing genetically engineered T cells into patients, researchers aim to bolster the immune response against cancer, offering a personalized and potentially curative treatment option. This groundbreaking technology holds promise for addressing various malignancies and represents a significant stride towards more effective and precise cancer therapies.